Claims for Patent: 9,157,084
✉ Email this page to a colleague
Summary for Patent: 9,157,084
Title: | Furin-knockdown bi-functional RNA |
Abstract: | Compositions and methods to attenuate the immunosuppressive activity of TGF-.beta. through the use of bi-functional shRNAs was substituted therefor described herein. The bi-functional shRNAs of the present invention knocks down the expression of furin in cancer cells to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene. |
Inventor(s): | Nemunaitis; John J. (Cedar Hill, TX), Senzer; Neil (Dallas, TX), Maples; Phillip B. (Pilot Point, TX), Rao; Donald (Dallas, TX) |
Assignee: | GRADALIS, INC. (Dallas, TX) |
Application Number: | 12/973,787 |
Patent Claims: | 1. An expression vector comprising: a first nucleic acid insert operably linked to a promoter, wherein the first insert encodes a human Granulocyte Macrophage Colony
Stimulating Factor (GM-CSF) cDNA; and a second nucleic acid insert operably linked to the promoter, wherein the second insert encodes one or more bifunctional short hairpin RNAs (shRNA) capable of hybridizing to one of more regions of a mRNA transcript
encoding furin, wherein at least one of the regions is selected from base sequences 300-318, 731-740, 1967-1991, 2425-2444, 2827-2851 or 2834-2852 of SEQ ID NO:2, thereby inhibiting furin expression via RNA interference, wherein each bifunctional short
hairpin RNA comprises a first stem-loop structure that comprises an siRNA component and a second stem-loop structure that comprises a miRNA component and wherein the shRNA incorporates siRNA (cleavage dependent) and miRNA (cleavage-independent) motifs.
2. The expression vector of claim 1, wherein a nucleotide sequence encoding a picornaviral 2A ribosomal skip peptide sequence is intercalated between the first and the second nucleic acid inserts. 3. The expression vector of claim 1, wherein the promoter is a CMV mammalian promoter. 4. The expression vector of claim 3, wherein the CMV mammalian promoter contains a CMV IE 5' UTR enhancer sequence and a CMV IE Intron A. 5. An expression vector comprising a bifunctional small hairpin construct specific for knockdown of furin, wherein the expression vector plasmid further comprises: a nucleic acid insert operably linked to a promoter, wherein the insert encodes one or more short hairpin RNAs (shRNA) capable of hybridizing to a region of a mRNA transcript encoding furin selected from at least one of base sequences 300-318, 731-740, 1967-1991, 2425-2444, 2827-2851 or 2834-2852 of SEQ ID NO:2, thereby inhibiting furin expression via RNA interference, wherein each bifunctional short hairpin RNA comprises a first stem-loop structure that comprises an siRNA component and a second stem-loop structure that comprises a miRNA component. 6. The expression vector of claim 5, wherein the siRNA component functions in a cleavage-dependent manner and the miRNA component functions in a cleavage-independent manner. 7. A composition for treating cancer comprising a therapeutically effective amount of cells transfected with an expression vector comprising a first nucleic acid insert operably linked to a promoter, wherein the first insert encodes GM-C SF and a second nucleic acid insert operably linked to the promoter, wherein the second insert encodes one or more short hairpin RNAs (shRNA) capable of hybridizing to one or more regions of a mRNA transcript encoding furin, wherein at least one of the regions is selected from base sequences 300-318, 731-740, 1967-1991, 2425-2444, 2827-2851 or 2834-2852 of SEQ ID NO:2, thereby inhibiting furin expression via RNA interference, wherein each bifunctional short hairpin RNA comprises a first stem-loop structure that comprises an siRNA component and a second stem-loop structure that comprises a miRNA component. 8. The composition of claim 7, wherein the GM-CSF is human. 9. The composition of claim 7, wherein the siRNA component functions in a cleavage-dependent manner and the miRNA component functions in a cleavage-independent manner. 10. The composition of claim 7, wherein a nucleotide sequence encoding a picornaviral 2A ribosomal skip peptide sequence is intercalated between the first and the second nucleic acid inserts. 11. The composition of claim 7, where the promoter is a CMV mammalian promoter, enhancer and intron. 12. The composition of claim 7, wherein the cells are xenograft expanded tumor cells. 13. The composition of claim 7, wherein the composition comprises 1.times.10.sup.7 cells to 2.5.times.10.sup.7 cells. 14. The composition of claim 7, wherein the composition further comprises a therapeutically effective dose of .gamma.IFN (gamma interferon). 15. The composition of claim 14, wherein the therapeutically effective dose of .gamma.IFN is 50 or 100 .mu.g/m.sup.2. |
Details for Patent 9,157,084
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2029-12-23 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2029-12-23 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2029-12-23 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.